American International Group Inc. boosted its position in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 14.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,191 shares of the medical research company’s stock after purchasing an additional 279 shares during the quarter. American International Group Inc.’s holdings in Exact Sciences were worth $206,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in EXAS. Park Place Capital Corp raised its holdings in Exact Sciences by 189.2% in the first quarter. Park Place Capital Corp now owns 376 shares of the medical research company’s stock worth $25,000 after purchasing an additional 246 shares in the last quarter. True Wealth Design LLC bought a new position in Exact Sciences in the fourth quarter worth about $30,000. TCI Wealth Advisors Inc. raised its holdings in Exact Sciences by 15,466.7% in the first quarter. TCI Wealth Advisors Inc. now owns 467 shares of the medical research company’s stock worth $32,000 after purchasing an additional 464 shares in the last quarter. Ameritas Advisory Services LLC bought a new position in Exact Sciences in the first quarter worth about $32,000. Finally, Money Concepts Capital Corp bought a new position in Exact Sciences in the fourth quarter worth about $36,000. 89.13% of the stock is currently owned by institutional investors.
Insider Activity at Exact Sciences
In related news, insider Everett Cunningham sold 13,007 shares of Exact Sciences stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $66.49, for a total value of $864,835.43. Following the sale, the insider now owns 37,909 shares of the company’s stock, valued at approximately $2,520,569.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Exact Sciences Price Performance
Shares of NASDAQ EXAS opened at $67.29 on Tuesday. The stock has a market capitalization of $12.17 billion, a price-to-earnings ratio of -42.32 and a beta of 1.46. Exact Sciences Co. has a 12 month low of $40.73 and a 12 month high of $100.77. The firm’s 50 day simple moving average is $66.20 and its 200-day simple moving average is $79.81. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.41 and a quick ratio of 2.13.
Exact Sciences Company Profile
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
- Five stocks we like better than Exact Sciences
- 3 Small Caps With Big Return Potential
- The most upgraded stocks in November have two things in common
- What is a Secondary Public Offering? What Investors Need to Know
- Monday.com rocked earnings like it’s the weekend
- Bank Stocks – Best Bank Stocks to Invest In
- Plan to own one retailer? Make it this one
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.